Skip to main content Skip to main navigation menu Skip to site footer

Graves’ disease: A review in diagnosis and management


Background: Graves’ disease is the leading cause of hyperthyroidism condition in the world. The incidence of Graves’ disease in the world reaches 20-50 cases per 100,000 population per year. Graves’ disease can cause somatic, psychiatric, and cosmetic problems in the patient. In some cases, it caused a decreased quality of life and death if not appropriately managed. Hence, appropriate diagnosis and management should be made to prevent the progression of the disease.

Aim: This literature review aims to review the diagnosis and management of Graves’ disease.

Conclusion: Graves’ disease is an autoimmune disease that causes hyperthyroidism by stimulating the thyroid gland to produce thyroid hormone. History taking and laboratory investigation can be done to establish a diagnose of Graves’ disease. Treatment, including the use of anti-thyroid drugs, radioiodine therapy, and surgery. Monitoring should be done periodically during and after the course of treatment to prevent relapse.


  1. Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol. 2015;3:286-95.
  2. Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves’s' disease-real life data. Endocrine. 2017;56(3):568-578
  3. De Leo S et al. Hyperthyroidism. Lancet. 2016;388:906.
  4. Brix TH, Kyvik KO, Christensen K, and Hegedus L. Evidence for a major role of heredity in Graves’s Disease: A population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab. 2001;86: 930-934
  5. Laurberg P, Pedersen KM, Vestegaard H, and Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low intake area vs. high incidence of Graves’ Disease in the young in a high iodine intake area : Comparative surveys of thyrotoxicosis epidemiology in East Jutland Denmark and Iceland. J. Intern. Med. 1991;229: 415-420
  6. Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology. 2009; 150: 519-29.
  7. Martin A, Schwartz AE, Friedman EW, Davies TF. Successful production of intrathyroidal human T cell hybridomas: evidence for intact helper T cell function in Graves’s’ disease. J Clin Endocrinol Metab. 1989; 69: 1104-8.
  8. Rapoport B, McLachlan SM. Graves’ hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metab. 2014;99:4060-1.
  9. Delpita A, Rachmawati B. Hubungan kadar ferritin dengan TSH dan FT4 akibat transfusi berulang pada penderita thalassemia di RSUP Dr. Kariadi, Semarang, Indonesia. Intisari Sains Medis. 2019;10(2):403-407.
  10. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362: 726-38.
  11. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression: insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998; 273: 29615-25.
  12. Wémeau JL, Klein M, Sadoul JL, Briet C, Vélayoudom-Céphise FL. Graves’s' disease: Introduction, epidemiology, endogenous, and environmental pathogenic factors. Ann. Endocrinol. (Paris). 2018;79(6):599-607
  13. Ross DS et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343.
  14. Biondi B et al. The 2015 European Thyroid Association Guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4:149.
  15. Rago T, Cantisani V, Ianni F, Chiovato L, Garberoglio R, Durante C, et al. Thyroid ultrasonography reporting: consensus of Italian Thyroid Association (AIT), Italian Society of Endocrinology (SIE), Italian Society of Ultrasonography in Medicine and Biology (SIUMB) and Ultrasound Chapter of Italian Society of Medical Radiology (SIRM). J. Endocrinol. Invest. 2018;41(12):1435-1443.
  16. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.
  17. Kotwal A, Stan M. Thyrotropin Receptor Antibodies-An Overview. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1): S20-S27.
  18. Subekti I, Pramono LA. Current Diagnosis and Management of Graves’ Disease. Acta Med Indones. 2018;50(2):177-182.
  19. Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW. Predicting outcomes and complications following radioiodine therapy in Graves' thyrotoxicosis. Clin. Endocrinol. (Oxf). 2019;90(1):192-199.
  20. Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K. Thyroid surgery for Graves’ disease and Graves’ ophthalmopathy. Cochrane Database Syst Rev.2015;11:CD010576.
  21. Feroci F, Rettori M, Borrelli A, et al. A systematic review and meta-analysis of total thyroidectomy versus bilateral subtotal thyroidectomy for Graves’ disease. Surgery. 2014;155: 529-40.
  22. Andersen SL, Olsen J, Laurberg P. Antithyroid drug side effects in the population and in pregnancy. J Clin Endocrinol Metab. 2016;101:1606-14.
  23. Boboridis KG, Uddin J, Mikropoulos DG, et al. Critical appraisal on orbital decompression for thyroid eye disease: a systematic review and literature search. Adv Ther. 2015;32: 595-611.
  24. Qian J. [The stepwise establishment of standardized treatment for the thyroid eye disease]. Zhonghua Yan Ke Za Zhi. 2017;53(6):404-407.
  25. Wiersinga WM: Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5:134.

How to Cite

Dwisaputra, I. G. N. B. H., & Prabawa, I. M. Y. (2020). Graves’ disease: A review in diagnosis and management. Intisari Sains Medis, 11(3), 1328–1332.




Search Panel

I Gusti Ngurah Bagus Hindra Dwisaputra
Google Scholar
ISM Journal

I Made Yoga Prabawa
Google Scholar
ISM Journal